| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected and Quantified |
|---|
| Creation Date | 2005-11-16 15:48:42 UTC |
|---|
| Update Date | 2023-05-30 20:55:57 UTC |
|---|
| HMDB ID | HMDB0000226 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Orotic acid |
|---|
| Description | Orotic acid is classified as a pyrimidinemonocarboxylic acid. That is it is a uracil bearing a carboxy substituent at position C-6. It is also classified as a pyrimidinedione and a carboxylic acid. Orotic acid is a minor dietary constituent. Indeed, until it was realized that it could be synthesized by humans, orotic acid was known as vitamin B-13. The richest dietary sources of orotic acid are cow's milk and other dairy products as well as root vegetables such as carrots and beets. Dietary intake probably contributes to a basal rate of orotic acid excretion in urine because fasting decreases excretion by ~50%. However, it is now apparent that most urinary orotic acid is synthesized in the body, where it arises as an intermediate in the pathway for the synthesis of pyrimidine nucleotides. Orotic acid is converted to UMP by UMP synthase, a multifunctional protein with both orotate phosphoribosyltransferase and orotidylate decarboxylase activity. The most frequently observed inborn error of pyrimidine nucleotide synthesis is a mutation of the multifunctional protein UMP synthase (UMP synthase deficiency or orotic aciduria). This disorder prevents the conversion of orotic acid to UMP, and thus to other pyrimidines. As a result, plasma orotic acid accumulates to high concentrations, and increased quantities appear in the urine. Indeed, urinary orotic acid is so markedly increased in individuals harboring a mutation in UMP synthase that orotic acid crystals can form in the urine. The urinary concentration of orotic acid in individuals suffering from orotic aciduria can be of the order of millimoles of orotic acid per millimole creatinine. By comparison, the urinary level in unaffected individuals is ~ 1 ¬umol/mmol creatinine (PMID: 17513443 ). Orotic aciduria is characterized by megaloblastic anemia and orotic acid crystalluria that is frequently associated with some degree of physical and mental retardation. These features respond to appropriate pyrimidine replacement therapy and most cases appear to have a good prognosis. When present in sufficiently high levels, orotic acid can act as an acidogen and a metabotoxin. An acidogen is an acidic compound that induces acidosis, which has multiple adverse effects on many organ systems. A metabotoxin is an endogenously produced metabolite that causes adverse health effects at chronically high levels. Chronically high levels of orotic acid are associated with at least seven inborn errors of metabolism, including argininemia, LPI syndrome (lysinuric protein intolerance), hyperornithinemia-hyperammonemia-homocitrullinuria (HHH), OTC deficiency, citrullinemia type I, purine nucleoside phosphorylase deficiency, and orotic aciduria. Orotic acid is broadly classified as an organic acid. Abnormally high levels of organic acids in the blood (organic acidemia), urine (organic aciduria), the brain, and other tissues lead to general metabolic acidosis. Acidosis typically occurs when arterial pH falls below 7.35. In infants with acidosis, the initial symptoms include poor feeding, vomiting, loss of appetite, weak muscle tone (hypotonia), and lack of energy (lethargy). These can progress to heart abnormalities, seizures, coma, and possibly death. These are also the characteristic symptoms of the untreated IEMs mentioned above. Many affected children with organic acidemias experience intellectual disability or delayed development. In adults, acidosis or acidemia is characterized by headaches, confusion, feeling tired, tremors, sleepiness, and seizures. |
|---|
| Structure | InChI=1S/C5H4N2O4/c8-3-1-2(4(9)10)6-5(11)7-3/h1H,(H,9,10)(H2,6,7,8,11) |
|---|
| Synonyms | | Value | Source |
|---|
| Orotsaeure | ChEBI | | Uracil-6-carboxylic acid | ChEBI | | Uracil-6-carboxylate | Generator | | Orotate | Generator | | 1,2,3,6-Tetrahydro-2,6-dioxo-4-pyrimidecarboxylic acid | HMDB | | 1,2,3,6-Tetrahydro-2,6-dioxo-4-pyrimidinecarboxylic acid | HMDB | | 1,2,3,6-Tetrahydro-2,6-dioxopyrimidin-4-carbonsaeure | HMDB | | 2,6-Dihydroxy-4-pyrimidinecarboxylic acid | HMDB | | 2,6-Dihydroxypyrimidine-4-carboxylic acid | HMDB | | 2,6-Dioxo-1,2,3,6-tetrahydro-pyrimidine-4-carboxylic acid | HMDB | | 2,6-Dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid | HMDB | | 6-Carboxy-2,4-dihydroxypyrimidine | HMDB | | 6-Carboxyuracil | HMDB | | 6-Uracilcarboxylic acid | HMDB | | Acide orotique | HMDB | | Acido orotico | HMDB | | Acidum oroticum | HMDB | | Animal galactose factor | HMDB | | Lactinium | HMDB | | Molkensaeure | HMDB | | ORO | HMDB | | Orodin | HMDB | | Oropur | HMDB | | Orotonin | HMDB | | Orotonsan | HMDB | | Orotsaure | HMDB | | Oroturic | HMDB | | Orotyl | HMDB | | Uracil-6-carbosaeure | HMDB | | Vitamin b13 | HMDB | | Whey factor | HMDB | | Zinc orotate | HMDB | | Orotate, zinc | HMDB | | Acid, orotic | HMDB | | Orotate, potassium | HMDB | | Potassium orotate | HMDB | | Orotate, sodium | HMDB | | Sodium orotate | HMDB |
|
|---|
| Chemical Formula | C5H4N2O4 |
|---|
| Average Molecular Weight | 156.0963 |
|---|
| Monoisotopic Molecular Weight | 156.017106626 |
|---|
| IUPAC Name | 2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid |
|---|
| Traditional Name | orotic acid |
|---|
| CAS Registry Number | 65-86-1 |
|---|
| SMILES | OC(=O)C1=CC(=O)NC(=O)N1 |
|---|
| InChI Identifier | InChI=1S/C5H4N2O4/c8-3-1-2(4(9)10)6-5(11)7-3/h1H,(H,9,10)(H2,6,7,8,11) |
|---|
| InChI Key | PXQPEWDEAKTCGB-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as pyrimidinecarboxylic acids. These are pyrimidines with a structure containing a carboxyl group attached to the pyrimidine ring. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Diazines |
|---|
| Sub Class | Pyrimidines and pyrimidine derivatives |
|---|
| Direct Parent | Pyrimidinecarboxylic acids |
|---|
| Alternative Parents | |
|---|
| Substituents | - Pyrimidine-6-carboxylic acid
- Hydropyrimidine carboxylic acid derivative
- Pyrimidone
- Hydropyrimidine
- Heteroaromatic compound
- Vinylogous amide
- Urea
- Lactam
- Azacycle
- Monocarboxylic acid or derivatives
- Carboxylic acid
- Carboxylic acid derivative
- Organic nitrogen compound
- Organic oxygen compound
- Organopnictogen compound
- Organic oxide
- Hydrocarbon derivative
- Organooxygen compound
- Organonitrogen compound
- Aromatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aromatic heteromonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 345.5 °C | Not Available | | Boiling Point | 656.00 to 657.00 °C. @ 760.00 mm Hg (est) | The Good Scents Company Information System | | Water Solubility | 1.82 mg/mL at 18 °C | Not Available | | LogP | -0.83 | SANGSTER (1994) |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 1.97 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 9.9591 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 5.47 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 194.3 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 749.9 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 367.3 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 64.7 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 240.4 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 70.5 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 283.8 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 295.2 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 363.3 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 647.0 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 108.3 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 859.9 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 231.5 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 288.0 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 770.3 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 265.7 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 376.1 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Orotic acid,1TMS,isomer #1 | C[Si](C)(C)OC(=O)C1=CC(=O)[NH]C(=O)[NH]1 | 1660.4 | Semi standard non polar | 33892256 | | Orotic acid,1TMS,isomer #2 | C[Si](C)(C)N1C(=O)C=C(C(=O)O)[NH]C1=O | 1759.8 | Semi standard non polar | 33892256 | | Orotic acid,1TMS,isomer #3 | C[Si](C)(C)N1C(C(=O)O)=CC(=O)[NH]C1=O | 1718.4 | Semi standard non polar | 33892256 | | Orotic acid,2TMS,isomer #1 | C[Si](C)(C)OC(=O)C1=CC(=O)N([Si](C)(C)C)C(=O)[NH]1 | 1776.9 | Semi standard non polar | 33892256 | | Orotic acid,2TMS,isomer #1 | C[Si](C)(C)OC(=O)C1=CC(=O)N([Si](C)(C)C)C(=O)[NH]1 | 1882.7 | Standard non polar | 33892256 | | Orotic acid,2TMS,isomer #1 | C[Si](C)(C)OC(=O)C1=CC(=O)N([Si](C)(C)C)C(=O)[NH]1 | 2153.2 | Standard polar | 33892256 | | Orotic acid,2TMS,isomer #2 | C[Si](C)(C)OC(=O)C1=CC(=O)[NH]C(=O)N1[Si](C)(C)C | 1776.5 | Semi standard non polar | 33892256 | | Orotic acid,2TMS,isomer #2 | C[Si](C)(C)OC(=O)C1=CC(=O)[NH]C(=O)N1[Si](C)(C)C | 1869.5 | Standard non polar | 33892256 | | Orotic acid,2TMS,isomer #2 | C[Si](C)(C)OC(=O)C1=CC(=O)[NH]C(=O)N1[Si](C)(C)C | 2114.8 | Standard polar | 33892256 | | Orotic acid,2TMS,isomer #3 | C[Si](C)(C)N1C(C(=O)O)=CC(=O)N([Si](C)(C)C)C1=O | 1849.0 | Semi standard non polar | 33892256 | | Orotic acid,2TMS,isomer #3 | C[Si](C)(C)N1C(C(=O)O)=CC(=O)N([Si](C)(C)C)C1=O | 1925.6 | Standard non polar | 33892256 | | Orotic acid,2TMS,isomer #3 | C[Si](C)(C)N1C(C(=O)O)=CC(=O)N([Si](C)(C)C)C1=O | 2119.8 | Standard polar | 33892256 | | Orotic acid,3TMS,isomer #1 | C[Si](C)(C)OC(=O)C1=CC(=O)N([Si](C)(C)C)C(=O)N1[Si](C)(C)C | 1933.3 | Semi standard non polar | 33892256 | | Orotic acid,3TMS,isomer #1 | C[Si](C)(C)OC(=O)C1=CC(=O)N([Si](C)(C)C)C(=O)N1[Si](C)(C)C | 1962.0 | Standard non polar | 33892256 | | Orotic acid,3TMS,isomer #1 | C[Si](C)(C)OC(=O)C1=CC(=O)N([Si](C)(C)C)C(=O)N1[Si](C)(C)C | 1920.7 | Standard polar | 33892256 | | Orotic acid,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)C1=CC(=O)[NH]C(=O)[NH]1 | 1891.3 | Semi standard non polar | 33892256 | | Orotic acid,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N1C(=O)C=C(C(=O)O)[NH]C1=O | 1975.4 | Semi standard non polar | 33892256 | | Orotic acid,1TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)N1C(C(=O)O)=CC(=O)[NH]C1=O | 1969.6 | Semi standard non polar | 33892256 | | Orotic acid,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)C1=CC(=O)N([Si](C)(C)C(C)(C)C)C(=O)[NH]1 | 2222.3 | Semi standard non polar | 33892256 | | Orotic acid,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)C1=CC(=O)N([Si](C)(C)C(C)(C)C)C(=O)[NH]1 | 2294.6 | Standard non polar | 33892256 | | Orotic acid,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)C1=CC(=O)N([Si](C)(C)C(C)(C)C)C(=O)[NH]1 | 2322.0 | Standard polar | 33892256 | | Orotic acid,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC(=O)C1=CC(=O)[NH]C(=O)N1[Si](C)(C)C(C)(C)C | 2188.6 | Semi standard non polar | 33892256 | | Orotic acid,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC(=O)C1=CC(=O)[NH]C(=O)N1[Si](C)(C)C(C)(C)C | 2300.7 | Standard non polar | 33892256 | | Orotic acid,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC(=O)C1=CC(=O)[NH]C(=O)N1[Si](C)(C)C(C)(C)C | 2300.5 | Standard polar | 33892256 | | Orotic acid,2TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)N1C(C(=O)O)=CC(=O)N([Si](C)(C)C(C)(C)C)C1=O | 2305.5 | Semi standard non polar | 33892256 | | Orotic acid,2TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)N1C(C(=O)O)=CC(=O)N([Si](C)(C)C(C)(C)C)C1=O | 2360.9 | Standard non polar | 33892256 | | Orotic acid,2TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)N1C(C(=O)O)=CC(=O)N([Si](C)(C)C(C)(C)C)C1=O | 2288.1 | Standard polar | 33892256 | | Orotic acid,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)C1=CC(=O)N([Si](C)(C)C(C)(C)C)C(=O)N1[Si](C)(C)C(C)(C)C | 2477.5 | Semi standard non polar | 33892256 | | Orotic acid,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)C1=CC(=O)N([Si](C)(C)C(C)(C)C)C(=O)N1[Si](C)(C)C(C)(C)C | 2575.2 | Standard non polar | 33892256 | | Orotic acid,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)C1=CC(=O)N([Si](C)(C)C(C)(C)C)C(=O)N1[Si](C)(C)C(C)(C)C | 2324.8 | Standard polar | 33892256 |
|
|---|
| Disease References | | Canavan disease |
|---|
- Tavazzi B, Lazzarino G, Leone P, Amorini AM, Bellia F, Janson CG, Di Pietro V, Ceccarelli L, Donzelli S, Francis JS, Giardina B: Simultaneous high performance liquid chromatographic separation of purines, pyrimidines, N-acetylated amino acids, and dicarboxylic acids for the chemical diagnosis of inborn errors of metabolism. Clin Biochem. 2005 Nov;38(11):997-1008. Epub 2005 Sep 1. [PubMed:16139832 ]
| | Uremia |
|---|
- Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W: Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003 May;63(5):1934-43. doi: 10.1046/j.1523-1755.2003.00924.x. [PubMed:12675874 ]
| | Colorectal cancer |
|---|
- Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016. [PubMed:27275383 ]
- Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016. [PubMed:27015276 ]
- Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18. [PubMed:25037050 ]
| | Crohn's disease |
|---|
- Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158. [PubMed:27609529 ]
| | Ulcerative colitis |
|---|
- Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158. [PubMed:27609529 ]
| | Ornithine transcarbamylase deficiency |
|---|
- Arranz JA, Riudor E, Rodes M, Roig M, Climent C, Rubio V, Sentis M, Burlina A: Optimization of allopurinol challenge: sample purification, protein intake control, and the use of orotidine response as a discriminative variable improve performance of the test for diagnosing ornithine carbamoyltransferase deficiency. Clin Chem. 1999 Jul;45(7):995-1001. [PubMed:10388475 ]
- Kopin AS, McBride EW, Chen C, Freidinger RM, Chen D, Zhao CM, Beinborn M: Identification of a series of CCK-2 receptor nonpeptide agonists: sensitivity to stereochemistry and a receptor point mutation. Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5525-30. doi: 10.1073/pnas.0831223100. Epub 2003 Apr 15. [PubMed:12697901 ]
- Drogari E, Leonard JV: Late onset ornithine carbamoyl transferase deficiency in males. Arch Dis Child. 1988 Nov;63(11):1363-7. [PubMed:3202644 ]
| | Orotic aciduria I |
|---|
- Grohmann K, Lauffer H, Lauenstein P, Hoffmann GF, Seidlitz G: Hereditary orotic aciduria with epilepsy and without megaloblastic anemia. Neuropediatrics. 2015 Apr;46(2):123-5. doi: 10.1055/s-0035-1547341. Epub 2015 Mar 10. [PubMed:25757096 ]
- G.Frauendienst-Egger, Friedrich K. Trefz (2017). MetaGene: Metabolic & Genetic Information Center (MIC: http://www.metagene.de). METAGENE consortium.
- Webster DR, Becroft DO, van Gennip AH, Van Kuilenburg AP. (2014). Hereditary Orotic Aciduria and Other Disorders of Pyrimidine Metabolism. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G. eds. The Online Metabolic and Molecular Bases of Inherited Disease New York, NY. http://ommbid.mhmedical.com/content.aspx?bookid=971§ionid=62636333. McGraw-Hill.
| | N-acetylglutamate synthetase deficiency |
|---|
- Schubiger G, Bachmann C, Barben P, Colombo JP, Tonz O, Schupbach D: N-acetylglutamate synthetase deficiency: diagnosis, management and follow-up of a rare disorder of ammonia detoxication. Eur J Pediatr. 1991 Mar;150(5):353-6. [PubMed:2044610 ]
| | Hyperornithinemia-hyperammonemia-homocitrullinuria |
|---|
- Rodes M, Ribes A, Pineda M, Alvarez L, Fabregas I, Fernandez Alvarez E, Coude FX, Grimber G: A new family affected by the syndrome of hyperornithinaemia, hyperammonaemia and homocitrullinuria. J Inherit Metab Dis. 1987;10(1):73-81. [PubMed:3106719 ]
| | Lysinuric protein intolerance |
|---|
- Rajantie J: Orotic aciduria in lysinuric protein intolerance: dependence on the urea cycle intermediates. Pediatr Res. 1981 Feb;15(2):115-9. doi: 10.1203/00006450-198102000-00006. [PubMed:7254935 ]
| | Phosphoenolpyruvate Carboxykinase Deficiency 1, Cytosolic |
|---|
- Santra S, Cameron JM, Shyr C, Zhang L, Drogemoller B, Ross CJ, Wasserman WW, Wevers RA, Rodenburg RJ, Gupte G, Preece MA, van Karnebeek CD: Cytosolic phosphoenolpyruvate carboxykinase deficiency presenting with acute liver failure following gastroenteritis. Mol Genet Metab. 2016 May;118(1):21-7. doi: 10.1016/j.ymgme.2016.03.001. Epub 2016 Mar 4. [PubMed:26971250 ]
|
|
|---|
| General References | - Shoemaker JD, Elliott WH: Automated screening of urine samples for carbohydrates, organic and amino acids after treatment with urease. J Chromatogr. 1991 Jan 2;562(1-2):125-38. [PubMed:2026685 ]
- Zieve L: Conditional deficiencies of ornithine or arginine. J Am Coll Nutr. 1986;5(2):167-76. [PubMed:3088083 ]
- Visek WJ: Ammonia: its effects on biological systems, metabolic hormones, and reproduction. J Dairy Sci. 1984 Mar;67(3):481-98. [PubMed:6371080 ]
- Arranz JA, Riudor E, Rodes M, Roig M, Climent C, Rubio V, Sentis M, Burlina A: Optimization of allopurinol challenge: sample purification, protein intake control, and the use of orotidine response as a discriminative variable improve performance of the test for diagnosing ornithine carbamoyltransferase deficiency. Clin Chem. 1999 Jul;45(7):995-1001. [PubMed:10388475 ]
- Sugio K, Gazdar AF, Albores-Saavedra J, Kokkinakis DM: High yields of K-ras mutations in intraductal papillary mucinous tumors and invasive adenocarcinomas induced by N-nitroso(2-hydroxypropyl)(2-oxopropyl)amine in the pancreas of female Syrian hamsters. Carcinogenesis. 1996 Feb;17(2):303-9. [PubMed:8625455 ]
- Finkelstein JE, Hauser ER, Leonard CO, Brusilow SW: Late-onset ornithine transcarbamylase deficiency in male patients. J Pediatr. 1990 Dec;117(6):897-902. [PubMed:2246687 ]
- Harris ML, Oberholzer VG: Conditions affecting the colorimetry of orotic acid and orotidine in urine. Clin Chem. 1980 Mar;26(3):473-9. [PubMed:7363468 ]
- Jakobs C, Sweetman L, Nyhan WL, Gruenke L, Craig JC, Wadman SK: Stable isotope dilution analysis of orotic acid and uracil in amniotic fluid. Clin Chim Acta. 1984 Nov 15;143(2):123-33. [PubMed:6391739 ]
- Visek WJ: Arginine and disease states. J Nutr. 1985 Apr;115(4):532-41. [PubMed:3884753 ]
- Mizutani Y, Wada H, Fukushima M, Yoshida O, Nakanishi H, Li YN, Miki T: Prognostic significance of orotate phosphoribosyltransferase activity in bladder carcinoma. Cancer. 2004 Feb 15;100(4):723-31. [PubMed:14770427 ]
- Valik D, Sedova Z, Starha J, Zeman J, Hruba E, Dvorakova L: Acute hyperammonaemic encephalopathy in a female newborn caused by a novel, de novo mutation in the ornithine transcarbamylase gene. Acta Paediatr. 2004 May;93(5):710-1. [PubMed:15174800 ]
- Mills GC, Schmalstieg FC, Newkirk KE, Goldblum RM: Cytosine and orotic acid in urine of immunodeficient children. Clin Chem. 1979 Mar;25(3):419-24. [PubMed:262183 ]
- Paradis D, Giguere R, Auray-Blais C, Draper P, Lemieux B: An automated method for the determination of orotic acid in the urine of children being screened for metabolic disorders. Clin Biochem. 1980 Aug;13(4):160-3. [PubMed:7449082 ]
- Potter M, Hammond JW, Sim KG, Green AK, Wilcken B: Ornithine carbamoyltransferase deficiency: improved sensitivity of testing for protein tolerance in the diagnosis of heterozygotes. J Inherit Metab Dis. 2001 Feb;24(1):5-14. [PubMed:11286382 ]
- van Kuilenburg AB, van Lenthe H, Loffler M, van Gennip AH: Analysis of pyrimidine synthesis "de novo" intermediates in urine and dried urine filter- paper strips with HPLC-electrospray tandem mass spectrometry. Clin Chem. 2004 Nov;50(11):2117-24. Epub 2004 Sep 16. [PubMed:15375016 ]
- Brosnan ME, Brosnan JT: Orotic acid excretion and arginine metabolism. J Nutr. 2007 Jun;137(6 Suppl 2):1656S-1661S. [PubMed:17513443 ]
- Elshenawy S, Pinney SE, Stuart T, Doulias PT, Zura G, Parry S, Elovitz MA, Bennett MJ, Bansal A, Strauss JF 3rd, Ischiropoulos H, Simmons RA: The Metabolomic Signature of the Placenta in Spontaneous Preterm Birth. Int J Mol Sci. 2020 Feb 4;21(3). pii: ijms21031043. doi: 10.3390/ijms21031043. [PubMed:32033212 ]
|
|---|